One of the things I find fascinating about this whole ordeal is the fact that many of the articles written since Patentlyo’s blog post all assume that this was some sort of “PUBLIC” rant or tirade. Everyone assumes that this was some sort of “Open Letter” to the USPTO that I wrote to shame this particular Examiner (in fact, this was just between the Examiner, his Senior Examiner and me…and no one else). In fact, this was a confidential letter and anyone who tells you anything to the contrary is full of shit, I don’t give a fuck what they tell you.

I’m gonna have to crowdsource this one because I’ve been doing research and can’t seem to figure out how Dennis Crouch was able to access my account with the USPTO. It has always been my understanding that patent applications less than 18 months old and their office action responses are to remain confidential. I’m starting to think that Patentlyo’s Dennis Crouch just wants me to believe that it is common knowledge that you can access anyone’s records there at the USPTO. However, from my own research I have found no evidence whatsoever that it is possible. And more importantly, I DON’T EVEN KNOW IF HIS ACTIONS WERE EVEN LEGAL!

The more I think about it, the more likely it is that Dennis Crouch may have broken a whole bunch of laws. When it comes to cyber crimes there are state laws (one for where he lives, possibly where I live, and that of Alexandria, Virginia (USPTO).

And then of course there are Federal laws as well such as the CFAA (Computer Fraud & Abuse Act) which makes it a felony to hack and steal documents similar to what Dennis mother fucking menace may have done.

You see, for the past several years I have taught myself how to build my own websites, everything…from A-Z. I can do HTML, the Videos, the graphics, the images, CSS, and even the SEO. And I think that I can build one hell of a website. For the past several years, I have had countless people call me out of the blue and ask me who built my website. When I reveal to them that it was me, they usually respond with something like, “No, really, who actually built your website?”

I love building websites. I get absorbed in it, and I can’t tell you how many times I have looked up at the clock to see “3:AM”, and wonder where the past 12 hours went. Some guys have video games, girls have shoe hunting expeditions, I have the website munchies. So, if any of you have gotten this far and think you need a website, go ahead and give me a call, and I’ll hook you up!

REMARKS: Are you drunk? No, seriously…are you drinking scotch and whiskey with a side of crack cocaine while you "examine" patent applications? (Heavy emphasis on the quotes.) Do you just mail merge rejection letters from your home? Is that what taxpayers are getting in exchange for your services? Have you even read the patent application? I'm curious. Because you either haven't read the patent application or are… (I don't want to say the "R" word) "Special."

So, tell me something Corky…what would it take for a patent application to be approved? Do we have to write patent applications in crayon? Does a patent application have to come with some sort of pop-up book? Do you have to be a family member or some big law firm who incentivizes you with some other special deal? What does it take Corky?

Perhaps you might want to take your job seriously and actually give a sh.t! What's the point in having to deal with you Special Olympics rejects when we should just go straight to Appeals? While you idiots sit around in bathtubs farting and picking your noses, you should know that there are people out here who actually give a sh.t about their careers, their work, and their dreams.

Principally, the article highlights how the US Patent Office acts responsibly when it engages constructively with principled criticisms and calls for reform, as it has during the passage and now implementation of the landmark Leahy–Smith America Invents Act of 2011.

Stuart J. H. Graham is an Expert Advisor at the US Patent and Trademark Office. He is an Assistant Professor, Scheller College of Business, Georgia Institute of Technology, Atlanta, Georgia, and is an attorney licensed in the State of New York. Saurabh Vishnubhakat is an Expert Advisor at the US Patent and Trademark Office. He is an Adjunct Professor at the Northern Virginia Community College, Alexandria, Virginia, and is an attorney licensed in the state of Illinois.

Ms. Ann Norman Assistant Editor, JEP relayed the following, "Stuart Graham was Chief Economist at USPTO and now is an Expert Advisor. That status changed only at the last minute, apparently, at the last stages of preparing to send this paper for printing…

"So the authors did disclose their potential conflicts of interest to us, and it was/is an editorial decision as to whether these conflicts were significant enough to post online. We can, in-fact still post the full disclosure statements with the paper, though of course it is too late to mention in the paper itself that the online disclosure statement exists."

For these initial roundtable events, this notice sets forth several topics to begin the Software Partnership discussion. The first topic relates to how to improve clarity of claim boundaries that define the scope of patent protection for claims that use functional language. The second topic requests that the public identify additional topics for future discussion by the Software Partnership. The third topic relates to a forthcoming Request for Comments on Preparation of Patent Applications and offers an opportunity for oral presentations on the Request for Comments at the Silicon Valley and New York City roundtable events.

"There's a possibility of competitive harm here," said Joseph Wayland, who served as the Justice Department's acting antitrust chief until last week, when he stepped down to return to private practice. Mr. Wayland said officials are devoting "huge energy, particularly at a senior level" to this and other antitrust issues surrounding patents.

If you're tired of the traditional roast, maybe it's time to try a more creative preparation—just be careful you don't run afoul of any patents. Here's an idea: with some skilled knife-work, you can slice a turkey into pieces that resemble various cuts of steak—and that method will only be under patent for another five years!

There are lots of unique recipes out there that call for a deboned turkey. For the inexperienced, it's probably wise to ask your butcher to do this for you—just make sure he doesn't use this method until 2022:

Luckily, there are plenty of open alternatives for the patent-savvy chef. Who needs those fancy new turkey cutlets when you can use this classic "method of preparing turkey ... in the form of a flat elongated slice or slices of raw fowl free from bones, tendons, membranes and skin." Mmmmmm. This patent was granted back in the 60s, so it's long since expired:

Or you could try this "method of preparing barbecued poultry such as turkey which closely simulates barbecued pork", patented in the early 70s and now free for all to follow in handy flow-chart form:

And finally, for the vegetarian in your life (assuming they prefer a lump of vaguely meat-shaped tofu to a nice falafel or something), there's this "method and apparatus for preparing a roast turkey analog (replica) from vegetarian ingredients". A patent was applied for in 2005, but appears not to have been granted...yet. Patents are retroactive to the date of filing, so only use this method if you want to gamble on the USPTO rejecting silly patents (then come play poker with me). All you need to do is make yourself what appears to be some kind of turkey mould, or possibly the sunken city of R'lyeh:

This is an exciting time, with much to be thankful for! Who knows what bold new turkey innovations the patent system will fuel next? A turkey-shaped gravy boat? A way of pulling the bones out from a different angle? A recipe where the sauce goes on after the broth? A toy turkey made out of a pine cone? Ooh, that's a good idea—I should call up the USPTO and... oh, never mind, some other Leigh beat me to it in 1927.

Indeed, Kappos suggested that the volume of patent litigation in the smartphone industry was a sign that the patent system was working as intended. "The explosion of litigation we are seeing is a reflection of how the patent system wires us for innovation," Kappos said. "It's natural and reasonable that innovators would seek to protect their breakthroughs using the patent system."

More recent research has estimated that litigation by patent trolls costs the economy at least $29 billion per year, and that figure may be as high as $83 billion.

Rather than engage in this empirical debate, or even acknowledge its existence, Kappos acted as though it was self-evident that stronger patents always create a larger incentive for innovation.

"To those commenting on the smartphone patent war with categorical statements that blame the so-called broken system on bad software patents, what I say is: get the facts. The facts don't support your position."

With all due respect, Mr. Kappos, we do have the facts. And they support the position of software patent critics.

Access Denied (content_filter_denied)

Your request was denied because this URL contains content that is categorized as: "Political/Activist Groups" which is blocked by USPTO policy. If you believe the categorization is inaccurate, please contact the USPTO Service Desk and request a manual review of the URL.

For assistance, contact USPTO OCIO IT Service Desk. (io-proxy4)

Now India has made another bold move in the field of healthcare:

From city hospitals to tiny rural clinics, India's public doctors will soon be able to prescribe free generic drugs to all comers, vastly expanding access to medicine in a country where public spending on health was just $4.50 per person last year.

The plan was quietly adopted last year but not publicized. Initial funding has been allocated in recent weeks, officials said.

Under the plan, doctors will be limited to a generics-only drug list and face punishment for prescribing branded medicines, a major disadvantage for pharmaceutical giants in one of the world's fastest-growing drug markets.

But it will also have a major impact on the Western pharma companies, since it will effectively lock their products out of one of the two most important markets for the future. Combined with the compulsory licensing of more modern drugs, the latest move by India is deeply troubling for the world's main drug companies. That's reflected in both Bayer's attempt to contest the compulsory licensing order, and USPTO deputy director Teresa Stanek Rea's extraordinary claim that the move was in violation of TRIPS, clearly not the case.

India's decision to adopt generics across its entire healthcare system also stands in stark contrast to provisions in TPP that will make it much harder for local manufacturers in signatory countries to produce generics legally. As a result, TPP looks more and more like an attempt to lock emerging countries into old and one-sided business models that are stacked against them.

Follow me @glynmoody on Twitter or identi.ca, and on Google+

Rea told the committee, saying she believes the issuance of the Indian compulsory license was in violation of the Agreement on Trade Related Aspects of Intellectual Property Rights, an international pact administered by the World Trade Organization which sets minimum standards for intellectual property regulation. Rea said the USPTO is working to stem the tide of IP infringement in foreign countries by the use of a host of training programs and educational efforts aimed at foreign officials and judges along with the placement USPTO overseas IP attaches in Thailand, China, Russia, India, Brazil and Egypt.

Article 31 of the TRIPS Agreement expressly permits compulsory licenses as does the much earlier Paris Convention on the Protection of Industrial Property. The U.S. Itself routinely makes government use of patented inventions pursuant to Congressional authority under 28 U.S.C. Sec. 1498, but also has other laws allowing compulsory licenses in specific circumstances. Compulsory licenses have been allowed globally in the vast majority of intellectual property regimes since the 19th century. And, the patent on Nexavar in India had been granted under a 2005 Amended Patents Act that clearly articulated compulsory licensing rights at the time that Bayer prosecuted its patent and the patent was granted.

Finally, and most to the point, the US signed the Doha Declaration on the TRIPS Agreement and Public Health that pointedly grants countries the right to issue compulsory licenses, to define the terms upon which such licenses are granted – without restrictions, and to define the emergency circumstances that permit licenses to be granted without any prior notice to or negotiation with the patent holder (note: these expedited, no-negotiation procedures were not used in the Natco case). Under the Doha Declaration, countries are permitted to issue compulsory licenses in order to ensure “access to medicines for all” – something that India has attempted to do via the license granted.

“I don’t want anyone to try to grow a unibrow because of me and then try to make money off of it,” Davis told CNBC. “Me and my family decided to trademark it because it’s very unique.”

1. How the hell does something like this get patented in the first place? There is a tremendous amount of prior art in the form of things like "one-time" use codes for video games and other digital offerings to limit the used sales market. And yet this still gets approved? USPTO examiner James D. Nigh should be ashamed for letting this piece of garbage get approved.
2. The claims here (the patent only has four) are so broad and so general, I don't see how it passes the non-obvious test, nor how it is anything more than mashing together a few different things that are widely available already and have been for years. After the KSR ruling the USPTO was supposed to reject broad patents that just combined basic concepts already found in the market.
3. How could a professor of economics actually think that locking up access to information is a good idea? That alone would make me avoid any class that he taught, as his understanding of information economics is way, way off.
4. It's sad that anyone in academia would think that this is a good idea. In an age where Harvard and MIT are investing a ton into opening up access, this guy is focused on locking it down.

All evidence suggests that patents continue to drive innovation in technology. At the time of his death, innovator Steve Jobs had more than 300 patents. Companies such as Apple have made transformative changes in our lives, made possible by massive investments made by intellectual property. But while such companies develop brand-new technologies and services, they also perform incremental innovation. Thus, IP conflicts arise as the byproducts of a very healthy overall innovation environment. The tech industry is characterized by extremely sharp drops in costs over time, extremely strong increases in performance, and multiple changes in market leads, with different companies leading at different points in time. That tremendously competitive marketplace is a sign of the critical role IP rights play in driving technology companies to invest, compete, create jobs, and drive exports.

All evidence suggests that patents continue to drive innovation in technology. At the time of his death, innovator Steve Jobs had more than 300 patents. Companies such as Apple have made transformative changes in our lives, made possible by massive investments made by intellectual property. But while such companies develop brand-new technologies and services, they also perform incremental innovation. Thus, IP conflicts arise as the byproducts of a very healthy overall innovation environment. The tech industry is characterized by extremely sharp drops in costs over time, extremely strong increases in performance, and multiple changes in market leads, with different companies leading at different points in time. That tremendously competitive marketplace is a sign of the critical role IP rights play in driving technology companies to invest, compete, create jobs, and drive exports.

On methodological question:

The IP report focused on identifying “IP-intensive industries and examining their characteristics and contributions to the overall economy.” One measure of the contribution of these industries to the overall economy is the number of jobs in these industries; other measures we looked at are value-added; wages earned by workers in these industries; and exports.

According to the report, the number one IP intensive industry in terms of employment is “grocery stores,” with 2.5 million jobs. The six industries with more than a million jobs are the following:

1. Grocery stores, 2.5 million
2. Depository credit intermediation, 1.7 million
3. Computer systems and designs,. 1.6 million
4. Insurance carriers, 1.4 million
5. Management and technical consultants, 1.2 million
6. Clothing stores, 1.1 million

These are just a few of the industries the Department of Commerce calls IP-Intensive: Oil and gas extraction, Residential building construction, Grain and oilseed milling, Dairy product manufacturing, Lessors of real estate, Gambling industries, Household and institutional furniture, Pulp, paper, and paperboard mills, Sporting goods and musical instrument stores, Travel arrangement and reservation, etc.

Industries like these overwhelm the statistics on jobs for the more legitimate choices, such as Sound recording industries (just 36.4 thousand jobs), or Software publishers (259.8 thousand), making it seem as though the IP-Intensive industries are truly enormous employers.

[....]

It was also pointed out that while the Software publishing sector was a high wage sector, it was a relatively small employer of the professionals in its key occupations. For example, less than 5 percent of computer programmers work for Software publishers. What do the other 95+ percent of computer programmers do? Quite a few build applications and services than use various open source free software platforms, which are both inexpensive and easy to customize.

And, where is the growth for employment? For the computer, mathematical science occupations, the rate of growth is three times higher outside of the Software Publishers Sector than inside the sector. So what can USPTO or the Economics and Statistics Administration tell us about the relationship between IP and employment? Not much, other than grocery stores, insurance companies and oil companies use a lot of trademarks, and not many people work in the sound recording industry.

After we left the TACD plenary where the IP and employment report was discussed, the TACD IP Policy Committee met with four US IP/Trade agencies, and three Directorates of the European Union. The meeting began with a US trade official telling us about this new employment study that showed the need for ACTA. No kidding. And, we will certainly continue to hear about this report, with very little understanding of how it was put together.

There is no easy solution to these problems. Reducing patent protection is not likely to solve these thorny issues.... To the contrary, the lack of effective patent protection can be one of the many factors which prevent the appropriate medicines from reaching the neediest patients in DC and LDCs. Weakening the patent rights granted to pharmaceutical researchers and manufacturers in certain markets not only removes or reduces the incentive to develop new medicines, but also reduces the incentives for innovative medicine developers to invest in those countries and harness their innovation to solving the public health challenges that disproportionately affect developing countries, and are not being solved in other ways.

Weakening patent protection for innovative medicines is not a productive approach to improving availability of health care, because many other factors other than patents more directly affect the availability of medicines.

The proof of the weakness of that argument is that although most medicines on the World Health Organization’s List of Essential Medicines are not protected by patents, their availability in many markets is still limited. This is particularly true in DC/LDCs. Many other factors affect the availability of all medicines, patented or not.